Bedaquiline, pretomanid, linezolid,  and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis:  a systematic review

Silva1, Denise Rossato; Fernandes2, Flávia Fonseca; Ferreira3, Juliana Carvalho; Bernando4, Wanderley; Dalcolmo5, Margareth Maria Pretti; Johansen6, Fernanda Dockhorn Costa; Mello7, Fernanda Carvalho de Queiroz

doi:https://dx.doi.org/10.36416/1806-3756/e20240295

891
Views

Back to summary

Open Access

Peer-Reviewed
Meta-análise

Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review

Denise Rossato Silva1, Flávia Fonseca Fernandes2, Juliana Carvalho Ferreira3, Wanderley Bernando4, Margareth Maria Pretti Dalcolmo5, Fernanda Dockhorn Costa Johansen6, Fernanda Carvalho de Queiroz Mello7

DOI: https://dx.doi.org/10.36416/1806-3756/e20240295

How to cite this article

Silva1 DR, Fernandes2 FF, Ferreira3 JC, Bernando4 W, Dalcolmo5 MMP, Johansen6 FDC, et al. Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. J Bras Pneumol. 2024;50(6):e20240295